Some States Getting Smaller Share Of Vaccines Than What They Need, Says SBI Research
Some Indian states are receiving a smaller share of Covid-19 vaccines from the central government than what they currently require, according to SBI Research.
“We find that certain states like Maharashtra, Uttar Pradesh, Delhi and Chhattisgarh are getting lower vaccine doses than they require,” SBI Research said in its latest Ecowrap publication. “Thus these states have to procure large number of vaccines from the manufacturers to fill the gap.”
SBI Research's analysis is based on each state's adult population, overall death rate, new Covid-19 infections and deaths in the last month. They used the combination of this data to estimate the proportion of vaccines each states should be ideally getting. That was then compared with the actual share of vaccines allotted to states so far.
Maharashtra and Uttar Pradesh were the two stand-out states that need a lot more vaccines than what they are getting, according to the report. “Maharashtra should have a share of 17.8% in the total vaccine allocation but as per the current data its share is only 10.1%,” it said. “Even if we include the vaccine doses in pipeline, the share is going to rise marginally to 10.2% which will still be below the required doses.”
On the other hand, states like Gujarat, Rajasthan, Kerala, Odisha and West Bengal are recieving a larger allocation of vaccines than what is required given their population and Covid-19 infection counts.
The central government's supply of vaccines to states is only meant for those aged above 45 and the frontline workers. For the 18-44 age group, states have to procure doses directly from the vaccine manufacturers.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.